contraindications to glp-1 glp 1 receptor agonists Clinical Recommendations Manage Gastrointestinal Adverse Events in Patients Treated with Receptor Agonists: A Multidisciplinary Expert Consensus Planning to start a GLP-1

Clinical Trials and Refill Programs Trial medications and recurring deliveries demand consistent, repeatable results

In a new trend that many have dubbed Ozempic babies, women are reporting on social media that they are becoming pregnant after using GLP-1 drugs like Ozempic (semaglutide) for weight loss

Ileus can cause problems like abdominal swelling, constipation and vomiting

Our review of the clinical trial pipeline reveals 39 new GLP-1 drugs in development from 34 companies, with only seven among the top 20 pharmaceutical companies

The goal of this tracker is to provide insight into recent trends in GLP-1 prescribing rates

Mayo Clinics ENDO 2025 study of 120 postmenopausal women found tirzepatide plus HRT produced 17% weight loss vs 14% alone over 18 months, with 45% of HRT users hitting 20%+ loss vs 18% of non-users (see our tirzepatide vs semaglutide analysis)